FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE CITATION** 

Several sheets if necessary)

ATTY. DOCKET NO. QA0280 NP APPLICATION NO. 10/773,790 APPLICANT HYNES ET AL. FILING DATE FEBRUARY 6, 2004

Group 1626

FEB 1 0 ZOES WHITE

### **U.S. RELATED PATENT APPLICATIONS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						

### **U.S. PATENT APPLICATION PUBLICATIONS**

		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
KS	AB	2002/0065270	5/30/02	Moriarty et al.			
KS	AC	2002/0137747	9/26/02	Moriarty et al.			
KS	AD	2003/0114504	6/19/03	Webster et al.	·		
KS	AE	2004/0024208	2/5/04	Das et al.			
KS	AF	2004/0039033	2/26/04	Atwal et al.			
KS	AG	2004/0054186	3/18/04	Das et al.			
KS	АН	2004/0073026	4/15/04	Das et al.			
KS	Al	2004/0077875	4/22/04	Das et al			

### **U.S. PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
KS	AJ	4,200,750	4/29/80	Warner, Jr. et al.			
KS	AK	5,712,279	1/27/98	Biller et al.			
KS	AL	5,739,135	4/14/98	Biller et al.		•	
KS	AM	5,760,246	6/2/98	Biller et al.			
KS	AN	6,184,231	2/6/01	Hewawasam et al.			
KS	AO	6,262,094	7/17/01	Hoefle et al.			<del>-</del>
KS	AP	6,262,096	7/17/01	Kim et al.			
KS	'AQ	6,548,529	4/15/03	Robl et al.			
KS	AR	6,596,746	7/22/03	Das et al.			
KS	AS	6,605,599	8/12/03	Vite et al.			<u> </u>
KS	AT	6,706,720	3/16/04	Atwal et al.	i		

**EXAMINER** 

/Kamal Saeed/

DATE CONSIDERED

08/31/2006

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO. QA0280 NP APPLICATION NO. 10/773,790 APPLICANT HYNES ET AL. FILING DATE FEBRUARY 6, 2004

Group 1626

## **FOREIGN PATENT DOCUMENTS**

	1	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS	TRAN	SLATION NO
						s		
KS	2AA	WO 00/62778	10/26/00	PCT '				
KS	2AB	WO 01/10865	2/15/01	PCT				
KS	2AC	WO 02/96905	3/8/01	PCT ·				
KS	2AD	WO 01/35959	5/25/01	PCT				
KS_	2AE	WO 01/70671	9/27/01	PCT				
KS	2AF	WO 01/74811	10/11/01	PCT				
KS	2AG	WO 02/45652	6/13/02	PCT				
	AH							
•	Al							
	AJ							
	AK				· .			
	AL				1			
	AM							
	AN	•	-		,			
	AO							
	AP							
	AQ							
	AR							
<del></del>	AS							
	AT							
<del></del>	AU							
	AV							<u> </u>
	AW							
	AX							<u> </u>
	AY	•						_
	AZ							<del> </del>
EXAMIN		/Kamal Saeed/	′	DATE CONSIDERED . 0	8/31/20	06	<u> </u>	

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

### INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. QA0280 NP APPLICATION NO. 10/773,790 APPLICANT HYNES ET AL. FILING DATE FEBRUARY 6, 2004

Group 1626

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		OTTEN DOCUMENTO (mondaing Addio), Title, Date, Ferdinest pages, Etc.)					
KS	ЗАА	Ahn, HS. et al., "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity", J. Med. Chem., Vol. 40, No. 14, pp. 2196-2210 (1997)					
KS	ЗАВ	Henry, J.R. et al., "p38 mitogen-activated protein kinase as a target for drug discovery", Drugs of the Future, Vol. 24, No. 12, pp. 1345-1354 (1999)					
KS	заС	Moreland, L.W. et al., "Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial", Ann. Intern. Med., Vol. 130, No. 6, pp. 478-486 (1999)					
KS	3AD	Rankin, E.C.C. et al., "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis", British Journal of Rheumatology, Vol. 34, No. 4, pp. 334-342 (1995)					
KS	3AE	Raingeaud, J. et al., "MKK3- and MKK6-Regulated Gene Expression Is Mediated by the p38 Mitogen-Activated Protein Kinase Signal Transduction Pathway", Molecular and Cellular Biology, Vol. 16, No. 3, pp. 1247-1255 (1996)					
KS	3AF	Salituro, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases", Current Medicinal Chemistry, Vol. 6, No. 9, pp. 807-823 (1999)					
KS	3AG	Zhao, R. et al., "A new facile synthesis of 2-aminothiazole-5-carboxylates", Tetrahedron Letters, Vol. 42, pp. 2101-2102 (2001)					
	АН						
	Al						
	AJ						
	AK						
	AL						
	АМ	·					
	AN						
EXAMINE	R	/Kamal Saeed/ DATE CONSIDERED 08/31/2006					

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.